Clinical trial NCT04059796: Comparison of Gemini III Rev 2 Implanted in Conjunction With an Approved IOL vs Eyes Implanted With an Approved IOL
Official title: Clinical Investigation of OMEGA Gemini Capsule, Model Gemini Capsule 3 Rev 2 in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Lead sponsor: Omega Ophthalmics
Sponsor class: INDUSTRY
First posted: 2019-08-16
Enrollment: 6
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective, observational, randomized, controlled, paired eye, subject-masked design.

Detailed description: Subjects will be randomly assigned to which eye will receive the Omega capsule Gemini 3 with an approved monofocal or Toric intraocular lens. Fellow eyes will receive an approved monofocal or Toric IOL (no Omega capsule).

Eyes randomized to receive one of the Gemini capsules (both models) will be eligible to have a secondary procedure (post 1-month postoperative visit) to correct refractive error.

Eligibility criteria: Inclusion Criteria:

* 40 years of age or older at the time of surgery diagnosed with bilateral cataracts
* Able to understand and sign an informed consent
* Willing and able to complete all study visits and assessments required for the study
* Calculated lens power within the available range
* Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present
* Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation
* Potential postop visual acuity of 20/25 or better in the judgment of the surgeon
* Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography
* Clear intraocular media other than cataract
* Preop endothelial cell density of 2000 cells/mm2 or more

Exclusion Criteria:

* Subject's best corrected vision is light perception or no light perception in either eye
* Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.
* Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.
* Eyelid abnormalities causing lagophthalmos.
* Significant anterior blepharitis or meibomian gland dysfunction
* Corneal abnormalities or conditions, other than regular topographic corneal astigmatism
* Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)
* Abnormalities of the iris including trans-illumination defects
* Pupil abnormalities (abnormally shaped, fixed or non-reactive)
* Pharmacologic dilation less than 7 mm
* Axial length \<22.5mm
* Lens thickness \<4.1 mm
* Anterior chamber depth \>2.8mm
* Extremely shallow anterior chamber \<2.0mm
* Prior ocular surgery
* Epiretinal membrane
* Macular edema
* Retinal tears including operculated holes
* Amblyopia
* Glaucoma of any kind
* Pseudoexfoliation syndrome
* History of uveitis/iritis
* Diabetic retinopathy
* Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis).
* Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) or similar medications
* Average Keratometry \<38D or \> 48D by topography
* Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules.
* History of ocular trauma
* Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes

Primary outcomes:
measure: Absence of fusion of peripheral anterior and posterior capsule to the intraocular lens
timeFrame: 6 month Postop Visit
Secondary outcomes:
Other outcomes:
Locations:
city: San José
country: Costa Rica
facility: Clinica 20/20
Study officials:
name: Claudio Orlich, MD
role: PRINCIPAL_INVESTIGATOR
References: